Clinical trials: Eczema/Atopic Dermatitis
Atopic Dermatitis (AD), Psoriasis (PsO)
Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
The goal of this clinical trial is to study the drug LPX-TI641 in patients with atopic dermatitis and psoriasis. We will compare the safety and tolerability of LPX-TI641 to placebo ( a look-alike solution) that contains no drug.
- Trial name
- NCT06982352
- Testing
- LPX-TI641
- Where
- 3 sites in United States, Jordan
- Volunteers
- 48 people
- Sponsor
- LAPIX Therapeutics Inc.
Pruritus, Atopic Dermatitis
Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis
Kappa-opioid receptors mediate the sensation of itch in animals and humans. Asimadoline is an orally active, selective kappa-opioid receptor agonist and has demonstrated efficacy in several preclinical pruritus models.
- Trial name
- NCT02475447
- Testing
- Asimadoline
- Where
- 22 sites in United States
- Volunteers
- 249 people
- Sponsor
- Tioga Pharmaceuticals
Atopic Dermatitis (AD)
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profiles of TLL-018 in Patients With Moderate-to-Severe Atopic Dermatitis
This is an operationally seamless Phase II/III, multicenter, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT07784816
- Testing
- TLL-018 tablets
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Atopic Dermatitis
Investigation of Flare and Remission in Subjects With Atopic Dermatitis
The trial is an exploratory, single-centre, uncontrolled, open-label, interventional trial of up to 19 weeks' duration to investigate flare and remission in subjects with moderate-to-severe atopic dermatitis (AD) treated with…
- Trial name
- NCT03710044
- Testing
- Cyclosporine A
- Where
- Netherlands
- Sponsor
- LEO Pharma
Type 1 Diabetes, Allergic Rhinitis
Intervention in Chronic Pediatric Patients and Their Families.
This project consists of a psychological intervention in patients and their families with different chronic diseases in order to carry out a comparative study between medical pathologies to know which are the protective or risk…
- Conditions
- Type 1 Diabetes, Allergic Rhinitis, Allergic Asthma, Asthma
- Trial name
- FACTORADAPT (NCT04476433)
- Testing
- Ten Vida (10Vida)
- Where
- Spain
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Valencia
Atopic Dermatitis, Staphylococcus Aureus
Staphylococcal Toxins in Atopic Dermatitis and Eczema Herpeticum
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease. Clinical studies have demonstrated a link between staphylococcal skin colonization and the pathogenesis of AD, but the implication of bacterial…
- Conditions
- Atopic Dermatitis, Staphylococcus Aureus, Bacterial Toxins, Immune Response
- Trial name
- STADEH (NCT04274348)
- Testing
- Skin biopsies and blood samples
- Where
- 2 sites in France
- Volunteers
- 41 people
- Sponsor
- Poitiers University Hospital
Asthma, Allergic Rhinitis
Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)
The purpose of this study is to look at measures that will help scientists understand the way Omalizumab, an FDA-approved anti-allergy medication, works.
- Conditions
- Asthma, Allergic Rhinitis, Atopic Dermatitis
- Trial name
- Xolair (NCT00367016)
- Testing
- Omalizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, Davis
Atopic Dermatitis
Short Term Growth in Children With Atopic Dermatitis
Main objective:to assess short term growth in children with atopic dermatitis during treatment with tacrolimus 0.1% and mometasone furoate 0.1%. A singl blind randomised cross over trial including 20 children.
- Trial name
- NCT00236106
- Testing
- tacrolimus ointment 0.1%, mometasone furoate 0.1%
- Volunteers
- 20 people
- Sponsor
- Children´s Clinic, Randers
Atopic Dermatitis
Open-label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under Occlusion
This study will access the degree to which pimecrolimus is absorbed from pimecrolimus cream 1% into the blood when applied repeatedly under occlusion (i.e.
- Trial name
- NCT00925730
- Testing
- Pimecrolimus
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Novartis
Dermatologic Disease, Phobia
Efficacy of Targeted Intervention for Topical Steroid Phobia.
Topical steroids are an important component of treatment for many dermatological conditions, however 'Corticosteroid phobia' is a significant factor contributing to non adherence to prescribed therapy.
- Conditions
- Dermatologic Disease, Phobia, Adherence, Medication
- Trial name
- NCT03658252
- Testing
- Targeted education, Online disease specific forum
- Where
- Singapore
- Volunteers
- 270 people
- Sponsor
- National University Health System, Singapore
Atopic Dermatitis, Eczema
Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy
Atopic Dermatitis (AD) or eczema is a chronic relapsing inflammatory disease that affects 1-3% of the adults and up to 25% of the children in the United States.
- Trial name
- NCT01149759
- Testing
- Cyclosporine A
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Rockefeller University
Atopic Dermatitis, Eczema
HPA Axis Study in Japanese Adults
A multicenter, open-label study to evaluate the adrenal suppression potential of Mapracorat 0.1% ointment in Japanese adults with atopic dermatitis.
- Trial name
- NCT01407510
- Testing
- Mapracorat
- Where
- 3 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Bayer
Atopic Dermatitis
Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis
This is a Randomized, Double-blind, Vehicle-Controlled, Seamless and Adaptive-designed Phase II/III Study to Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Adult Patients with Mild-to-Moderate Atopic Dermatitis.
- Trial name
- MARBLE-23 (NCT04717310)
- Testing
- SHR0302 Ointment, Vehicle
- Where
- 31 sites in China
- Volunteers
- 645 people
- Sponsor
- Reistone Biopharma Company Limited
Atopic Dermatitis
Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Application of Topical BioLexa in Adult Healthy Subjects and Patients With Mild to Moderate Atopic Dermatitis
This is a Phase 1, randomised, double-blind, vehicle controlled study to determine the safety, tolerability, PK and efficacy of twice daily application of topical BioLexa™ lotion, administered for 28 days in adult healthy…
- Trial name
- NCT04544943
- Testing
- BioLexa- Cohort 1, BioLexa- Cohort 2, Gentamicin
- Where
- Australia
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Hoth Therapeutics, Inc.
Atopic Dermatitis
IDA (Immunothérapie de la Dermatite Atopique) Adult - Immunotherapy in Atopic Dermatitis
Atopic dermatitis (AD) is a chronic inflammatory disease of the skin. AD is very frequent, and involves T lymphocytes cells. Measles vaccination, as well as measles vaccine, induces a temporary immunosuppression; furthermore, an…
- Trial name
- IDA-Adult (NCT00820820)
- Testing
- ROUVAX
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Moderate-to-Severe Atopic Dermatitis
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as…
- Trial name
- ZENITH AD-2 (NCT07711418)
- Testing
- Rezpegaldesleukin
- Where
- 13 sites in United States
- Volunteers
- 510 people
- Sponsor
- Nektar Therapeutics
Atopic Dermatitis
A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis
A dose escalation, first-in-human study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of AK120 in healthy subjects and subjects with moderate- to- severe atopic dermatitis
- Trial name
- NCT04256174
- Where
- 13 sites in Australia, New Zealand
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Akesobio Australia Pty Ltd
Atopic Dermatitis
Pediatric Atopic Dermatitis (AD) Internet Survey
The purpose of this study is to evaluate whether participation in an Internet-based intervention helps improve atopic dermatitis treatment outcomes.
- Trial name
- NCT01385527
- Testing
- Weekly Internet survey, Topical Triamcinolone
- Sponsor
- Wake Forest University
Pruritus, Atopic Dermatitis
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis
This is a multicenter, randomized, double-blind, 4-arm, placebo-controlled study to evaluate the efficacy and safety of twice-daily (BID) oral difelikefalin (CR845) in adult subjects with atopic dermatitis (AD) and moderate to…
- Trial name
- KARE (NCT04018027)
- Testing
- difelikefalin 0.25 mg, difelikefalin 0.5 mg, difelikefalin 1.0 mg
- Where
- 40 sites in United States, Canada
- Volunteers
- 401 people
- Sponsor
- Cara Therapeutics, Inc.
Atopic Dermatitis
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.
- Trial name
- Adoring (NCT07265479)
- Testing
- Tapinarof cream, 1%, Vehicle Cream
- Where
- 46 sites in United States, Canada
- Volunteers
- 187 people
- Sponsor
- Organon and Co
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.